Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Name: Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Published: 2020
License: Public Domain

GlaxoSmithKline · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

multiple-myeloma

multiple myeloma, belantamab mafodotin, pomalidomide, dexamethasone, relapsed/refractory multiple myeloma, driving excellence in approaches to multiple myeloma 3 (dreamm 3), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Related documents